Single Domain Antibody Platforms Market is expected to witness an impressive CAGR of around 10% during 2020 to 2030
(1) NEW YORK, Dec. 11, 2020 /PRNewswire/ -- Monoclonal antibodies are highly efficient as therapeutics against viral infections, immune diseases, and cancer. However, they are large in size and unable to access some epitopes, besides the production cost being high. Hence, single-domain antibodies (sdAbs) is an alternative for monoclonal due to larger number of accessible epitopes, smaller size, relatively low production costs, and potent inhibitors against immune and viral diseases. Currently, single-domain antibodies are being developed against a number of viruses, including influenza viruse...
Source: finanznachrichten.de